Sodium-glucose cotransporter 2 inhibitors have demonstrated renal and cardiovascular protective effects in patients with CKD; however, their long-term effects in patients with AS and the underlying mechanisms remain to be clarified.<h4>Methods</h4>We conducted a single-arm, prospective study to examine the effect of dapagliflozin in patients with AS. Here, SLC5A2 is linked to chronic kidney disease.